Cabaletta Bio, Inc.（CABA）の財務CABACabaletta Bio, Inc.

Evaluating the bottom line, Cabaletta Bio, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -93.20%, provide a clear picture of how effectively CABA converts its operational activities into shareholder value.

In the context of the broader market, CABA competes directly with industry leaders such as RCKT and FATE. With a market capitalization of $249.23M, it holds a significant position in the sector. When comparing efficiency, CABA's gross margin of N/A stands against RCKT's N/A and FATE's 100.00%. Such benchmarking helps identify whether Cabaletta Bio, Inc. is trading at a premium or discount relative to its financial performance.

Cabaletta Bio has been experiencing significant losses, with net income to common shareholders consistently negative, reaching -51 million USD in Q2 2026. The company has a current ratio of 5.79, indicating good short-term financial health despite ongoing losses.